Home > Blog Tag

Blog Posts by Tag: COVID-19

Digital Pathology Trends and the Impact of COVID-19 on Speed of Adoption

Digital pathology was introduced decades ago as a way for sharing digital images across laboratories, enabling pathologists to work together on cases and enhance the accuracy of diagnostic techniques. Before the COVID-19 pandemic, U.S. adoption of digital pathology lagged behind most other developed countries.The COVID-19 pandemic accelerated the adoption of digital pathology in this country for...

Read


The CDC Offers a Multi-Virus Testing Option with the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay

With flu season typically starting in October and peaking between December and February, the Centers for Disease Control and Prevention (CDC) have developed two tests that identify the COVID-19 virus (SARS-CoV-2). The latest of these two tests, called the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay, tests for influenza A and B viruses as well as SARS-CoV-2.Along with the new test, the...

Read


3 Ways COVID-19 Will Impact Q4 Testing

As COVID continues to challenge the laboratory industry, XIFIN executives expect a 15% increase in COVID-19 volumes in the fall and regional labs to pick up overflow from larger, national players.This news was announced at a recent conference called “COVID-19’s Impact on Lab Industry Testing Volumes and Dynamics – September Update,” where XIFIN CEO Lâle White, XIFIN Executive Vice President...

Read


Is the FDA on a Dangerous Path? Overstepping LDT Authority Hampered COVID Response and Has Long Term Consequences for US Healthcare

As I recently discussed during my session at this year’s Executive War College, one important aspect of the COVID pandemic and laboratory testing during this time is how it exemplified the detrimental consequences of FDA overreach — which contributed in large part to testing delays and a hamstrung response in the outbreak’s early days — and how that overstepping poses risk going forward. On...

Read


Insurers Not Required to Reimburse COVID-19 Tests for Returning Workers

According to newly released guidelines from the Trump Administration, insurers will not have to cover COVID-19 screening tests mandated by employers for returning employees.Until these new guidelines, The Families First Coronavirus Response Act required insurers to cover COVID-19 testing without patient cost-sharing. The latest announcement said the law applies only to tests considered medically...

Read


XIFIN Data Reveals That COVID-19 Antibody Testing Volumes Are Surprisingly Low

Antibody testing volumes are lower than expected, while lab testing volumes have rebounded since March 2020, according to XIFIN data shared at a recent UBS audio conference. XIFIN’s Executive Chair and CEO Lâle White and Executive VP and General Manager of Diagnostic Services Kyle Fetter were on hand to share updates on nationwide COVID-19 testing and payor behavior. “COVID-19 has...

Read


Don’t Let a Crisis Misguide Your Choice in Revenue Cycle Management Systems for Outreach or Outpatient Labs

Hospital outreach program leaders are very familiar with management from the hospital or health system proposing that the current electronic health record (EHR) system is sufficient to support the outreach and outpatient laboratory revenue cycle management (RCM) process. “It’ll save money,” they say. “They (the vendor) tell us that it works fine for outreach and outpatient lab claims,” they add....

Read


CMS Has Largest-Ever Public Meeting – Discusses Pricing Lab Test Codes

On June 22, 2020, CMS held its largest-ever annual public meeting for pricing new laboratory test codes. In addition, it was the first-ever meeting held only virtually. Nearly 30 different organizations offered comments on some 130 new codes. A full transcript of the meeting is available at the blog “Discoveries in Health Policy.” The blog’s author, Bruce Quinn MD PhD, told XIFIN...

Read